Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an ...

Pyxis secured S$13 million in the first close of its S$18 million growth funding round, reflecting strong investor confidence in its vessel technology, commercial traction, and regional growth ...

Pyxis Oncology Inc. (NASDAQ: PYXS) on Thursday released preliminary data from its ongoing Phase 1 studies of micvotabart pelidotin (MICVO) for recurrent/metastatic head and neck squamous cell ...

Investing.com -- Pyxis Oncology Inc (NASDAQ:PYXS) stock tumbled 49.9% in premarket trading Thursday after investors expressed disappointment with preliminary data from the company’s experimental ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

BOSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced positive ...

本期推荐一款名为Pyxis的跨平台软件，其致力于解决离子淌度质谱成像（IM-MSI）数据处理中因缺乏全流程分析工具而阻碍技术应用的瓶颈问题。研究团队通过开发集成预处理、可视化、数据挖掘与代谢物鉴定功能的计算平台，成功实现对小鼠肾脏组织和THP-1单细胞 ...

Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The ...

BOSTON - Pyxis Oncology, Inc. (NASDAQ:PYXS) announced preliminary data from ongoing Phase 1 clinical studies of its antibody-drug conjugate micvotabart pelidotin (MICVO) in patients with ...

Jesse Calis spent a month with the Blackmagic PYXIS 12K cinema camera. His verdict: “If you are a serious filmmaker… this camera is really for you.” And how. Watch his full review of the Blackmagic ...

*For a limited time only. $2,000 off and a free toilet (install included) with the purchase and installation of a Safe Step Walk-In Tub. Note alternative offer of $1,000 off and a free toilet (install ...

46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M HNSCC at 5.4 mg/kg 71% confirmed ORR and 100% DCR observed with MICVO in ...